Study on AUNIP as a Novel Tumor Marker… | Clinical Trial

Key information

Conditions

Cervical Cancer Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Genital Diseases Genital Diseases, Female Genital Neoplasms, Female Neoplasms Neoplasms by Site Urogenital Diseases Urogenital Neoplasms Uterine Cervical Diseases Uterine Cervical Neoplasms Uterine Diseases Uterine Neoplasms

Age range

20 year–60 year

Sex eligibility

Female

Study type

Observational

About this study

Blood of all study participants of cervical cancer patients are collected to detect the expression of AUNIP, analyze the statistical correlation between the expression of cervical cancer AUNIP and clinicopathological parameters of patients, and preliminarily understand the expression of AUNIP in cervical cancer tumor tissues and its clinical diagnostic and progniostic value.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Study group inclusion criteria:

Women aged 20-60
There is a definite pathological diagnosis of cervical cancer

Healthy control group:

Women aged 20-60
No tumors in the uterus or other parts of the body
No inflammatory disease
Blood routine and blood biochemical tests are normal

Exclusion criteria

of the study group:

There are other lesions in the uterus and uterine adnexa

Exclusion criteria

of healthy control group:

Pregnant, lactating or menarche women
Women who are undergoing human papillomavirus (HPV) vaccination

Treatment and study plan

Detection of serum AUNIP expression

Diagnostic Test

The experiment is carried out according to the ELISA kit instructions, and the absorbance optic density (OD) value of the enzyme labeler at 450 nm is read. The protein concentration of AUNIP in the serum sample is calculated according to the standard curve.

Primary outcomes

AUNIP expression in serum

Time frame: through study completion, an average of 3 year

Serum AUNIP expression is detected by ELISA kit. The results will be recorded seperately.

Study contacts

Contact information is provided by the study sponsor or research team.

Lin Yuan, Ph.D.

CONTACT

[email protected]

0531-89269678

Sponsors and collaborators

Lead sponsor

Lin Yuan

Other

Registry information

Important dates

Study start: 2024
Primary completion: 2027
Study completion: 2029
First posted: Nov 7, 2023
Registry last updated: Nov 9, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Not Yet Recruiting